The presence and severity of diabetic retinopathy (DR) may be independently associated with subclinical cardiovascular disease (CVD) in patients with type 2 diabetes (T2D), suggesting the need for a rationalized screening for coronary artery disease in patients with T2D and DR.
The presence and severity of diabetic retinopathy (DR) may be independently associated with subclinical cardiovascular disease (CVD) in patients with type 2 diabetes (T2D), suggesting the need for a rationalized screening for coronary artery disease in patients with (T2D) and DR.
A study, published in BMJ Open Diabetes Research and Care, included 200 subjects with T2D who did not have a history of clinical CVD, as well as 60 age-matched non-diabetic subjects. In order to determine subclinical CVD, the researchers examined 2 parameters:
The researchers also performed coronary angio-CT and assessed DR through slit-lamp biomicroscopy and retinography.
“Once coronary artery disease manifests clinically, diabetic patients continue to have a worse prognosis compared with non-diabetic patients, both during acute ischemic events and during long-term follow-up. However, the increase in CVD risk is not homogeneous in patients with DM,” the authors said.
“In fact, a significant number of these patients will never experience CV complications, and current guidelines consistently advise against the routine use of prophylactic aspirin in patients with DM. Therefore, the early identification of diabetic patients at risk of developing CVD remains a challenge.”
The subjects with T2D demonstrated higher CACs than the non-diabetic control subjects, according to the results. Moreover, age, male gender, and the presence of DR were independently related to CACs over 400.
“In addition, an inverse relationship was observed between the degree of DR and CACs <10 area under the receiver operating characteristic curve (AUROC). The variables independently associated with the composite measurement of subclinical CVD were age, diabetes duration, the glomerular filtration rate, microalbuminuria, and the presence of DR (AUROC 0.71),” authors explained. “A relationship (P <.01) was observed between the presence and degree of DR and coronary stenosis.”
The study concluded that DR is an independent risk factor for identifying subclinical cardiovascular disease. Additionally, DR confers a higher risk of subclinical cardiovascular disease than factors contained in contemporary risk equations, researchers explained.
“The detection and grading of diabetic retinopathy permit us to identify a high-risk subset of diabetic population who might benefit most from tight control of cardiovascular risk factors. In addition, given that these patients are more prone to develop cardiovascular disease, they could be used to enrich the cohorts for future intervention trials, thus reducing sample size, duration, and costs of studies,” concluded the authors.
Reference:
Simó R, Bañeras J, Hernández C, et al. Diabetic retinopathy as an independent predictor of subclinical cardiovascular disease: baseline results of the PRECISED study [published online November 11, 2019]. BMJ Open Diabetes Res Care. doi:10.1136/bmjdrc-2019-000845.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Wearable Activity Tracker Data Enhance Patient Assessment in Lung Cancer
March 28th 2024This analysis included 119 patients with advanced lung cancer, who were evaluated on 3 facets of physical activity over 14 days of using the amuelink wearable device from Sony: metabolic equivalent tasks, distance walked, and steps taken.
Read More